Pub Date : 2024-11-01DOI: 10.1016/j.ogla.2024.06.004
Matthew N. Henderson MD , Hartej Singh BS , Lucy S. Guan MPH , Ang Li MD , Jonathan L. Prenner MD
Purpose
To provide relative citation ratio (RCR) benchmark data for the field of glaucoma.
Design
Cross-sectional bibliometric analysis.
Subjects
Fellowship-trained glaucoma faculty at Accreditation Council for Graduate Medical Education-accredited institutions.
Methods
Glaucoma faculty were individually indexed using the National Institutes of Health (NIH) iCite website. Publication count, mean RCR score, and weighted RCR score were collected for each author between May and August 2023 and included PubMed-listed articles from 1980 to 2023. Data were compared by sex, career duration, academic rank, and acquisition of a Doctor of Philosophy (PhD).
Main Outcome Measures
Total number of publications, mean RCR value, and weighted RCR value.
Results
Five hundred twenty-six academic glaucoma specialists from 113 institutions were indexed. These physicians produced highly impactful research with a median publication count of 13 (interquartile range [IQR] 4–38), median RCR of 1.41 (IQR 0.97–1.98), and median weighted RCR of 16.89 (4.80–63.39). Academic rank, career duration, and having a PhD were associated with increased publication count, mean RCR, and weighted RCR. Publication count and weighted RCR differed significantly by sex; however, no difference was observed with mean RCR.
Conclusions
Current academic glaucoma specialists have high mean RCR values relative to the NIH standard RCR value of 1. This benchmark data serve as a more accurate gauge of research impact within the glaucoma community and can be used to inform self, institutional, and departmental evaluations. Additionally, the mean RCR may provide an accurate metric for quantifying research productivity among historically underrepresented groups that are disadvantaged by time-dependent factors such as number of publications.
Financial Disclosure(s)
Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
{"title":"Evaluation of Research Productivity among Academic Glaucoma Specialists Using the Relative Citation Ratio","authors":"Matthew N. Henderson MD , Hartej Singh BS , Lucy S. Guan MPH , Ang Li MD , Jonathan L. Prenner MD","doi":"10.1016/j.ogla.2024.06.004","DOIUrl":"10.1016/j.ogla.2024.06.004","url":null,"abstract":"<div><h3>Purpose</h3><div>To provide relative citation ratio (RCR) benchmark data for the field of glaucoma.</div></div><div><h3>Design</h3><div>Cross-sectional bibliometric analysis.</div></div><div><h3>Subjects</h3><div>Fellowship-trained glaucoma faculty at Accreditation Council for Graduate Medical Education-accredited institutions.</div></div><div><h3>Methods</h3><div>Glaucoma faculty were individually indexed using the National Institutes of Health (NIH) iCite website. Publication count, mean RCR score, and weighted RCR score were collected for each author between May and August 2023 and included PubMed-listed articles from 1980 to 2023. Data were compared by sex, career duration, academic rank, and acquisition of a Doctor of Philosophy (PhD).</div></div><div><h3>Main Outcome Measures</h3><div>Total number of publications, mean RCR value, and weighted RCR value.</div></div><div><h3>Results</h3><div>Five hundred twenty-six academic glaucoma specialists from 113 institutions were indexed. These physicians produced highly impactful research with a median publication count of 13 (interquartile range [IQR] 4–38), median RCR of 1.41 (IQR 0.97–1.98), and median weighted RCR of 16.89 (4.80–63.39). Academic rank, career duration, and having a PhD were associated with increased publication count, mean RCR, and weighted RCR. Publication count and weighted RCR differed significantly by sex; however, no difference was observed with mean RCR.</div></div><div><h3>Conclusions</h3><div>Current academic glaucoma specialists have high mean RCR values relative to the NIH standard RCR value of 1. This benchmark data serve as a more accurate gauge of research impact within the glaucoma community and can be used to inform self, institutional, and departmental evaluations. Additionally, the mean RCR may provide an accurate metric for quantifying research productivity among historically underrepresented groups that are disadvantaged by time-dependent factors such as number of publications.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19519,"journal":{"name":"Ophthalmology. Glaucoma","volume":"7 6","pages":"Pages 531-538"},"PeriodicalIF":2.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141437862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.1016/j.ogla.2024.08.002
Kuldev Singh MD, MPH
{"title":"Reprint of: Transactional Care and the Looming Glaucoma Public Health Crisis","authors":"Kuldev Singh MD, MPH","doi":"10.1016/j.ogla.2024.08.002","DOIUrl":"10.1016/j.ogla.2024.08.002","url":null,"abstract":"","PeriodicalId":19519,"journal":{"name":"Ophthalmology. Glaucoma","volume":"7 6","pages":"Pages 515-517"},"PeriodicalIF":2.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142693924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.1016/j.ogla.2024.07.002
Jeremy C.K. Tan MD, FRANZCO , Yohei Hashimoto MD, PhD , Pierre Henry Gabrielle PhD , Catherine Creuzot Garcher MD, PhD , Andrew White PhD, FRANZCO , Hamish Dunn MBBS, FRANZCO , Mark Walland FRANZCO, FRACS , David Wechsler MBBS, FRANZCO , Louis Arnould MD, PhD , Mitchell Lawlor PhD, FRANZCO
<div><h3>Purpose</h3><div>To compare safety, effectiveness, and baseline predictors of failure in standalone primary Xen45 gel stent (Xen) versus trabeculectomy (Trab) in glaucoma.</div></div><div><h3>Design</h3><div>Retrospective study.</div></div><div><h3>Subjects</h3><div>Subjects that underwent primary Xen or Trab augmented by mitomycin-C with at least 12 months follow-up.</div></div><div><h3>Methods</h3><div>Multinational observational study of eyes in the Fight Glaucoma Blindness international registry</div></div><div><h3>Main Outcome Measures</h3><div>The primary outcome was success at 12 months defined by intraocular pressure (IOP) reduction ≥ 20% from baseline and ≤ threshold IOPs of 15, 18, and 21 mmHg with (qualified) or without (complete) medications and without secondary glaucoma surgery. Multivariable mixed effects Cox regression models were used to identify risk factors for failure in each cohort.</div></div><div><h3>Results</h3><div>A total of 701 eyes (Xen, 308; Trab, 393) of 596 subjects were included with baseline IOP being significantly higher (22.4 vs. 19.9 mmHg, <em>P</em> < 0.001) and baseline medications significantly lower in the Xen versus the Trab group (2.9 vs. 3.4, <em>P</em> < 0.001). Baseline visual field mean deviation was less severe in the Xen group (–9.47 vs. –13.04 dB, <em>P</em> < 0.001). The proportion of complete surgical success was significantly lower in the Xen versus Trab group across the 3 upper IOP limits at 12 months; 32% versus 52% at 15 mmHg, 37% versus 54% at 18 mmHg, and 39% versus 55% at 21 mmHg (<em>P</em> < 0.001). The incidence of postoperative numerical and symptomatic hypotony was lower in the Xen versus Trab group. In the Xen cohort, a higher failure rate was associated with Asian ethnicity (hazard ratio [HR], 1.97; 95% confidence interval (CI), 1.03–3.79) and use of oral acetazolamide at baseline (HR, 1.74; 95% CI, 1.13–2.70), whereas a lower failure rate was associated with diagnosis of ocular hypertension/open-angle glaucoma suspect (HR, 0.40; 95% CI, 0.20–0.82) and secondary open-angle glaucoma (HR, 0.46; 95% CI, 0.26–0.82). Exposure to prostaglandin analog was associated with greater failure in the Trab group (HR, 2.66; 95% CI, 1.18–6.01).</div></div><div><h3>Conclusions</h3><div>There was significantly greater complete success at 12 months across all complete success definitions for Trab compared with Xen, whereas the rate of postoperative hypotony was significantly lower in the Xen group. Asian ethnicity and use of oral acetazolamide at baseline were associated with greater failure in Xen, whereas exposure to prostaglandin analog was associated with greater failure in Trab patients. Such baseline predictors of success and failure may help guide patient selection for subconjunctival minimally invasive glaucoma surgery in patients undergoing surgical intervention.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the F
目的：比较独立初级Xen45凝胶支架（Xen）与小梁切除术（Trab）治疗青光眼的安全性、有效性和失败的基线预测因素：设计：回顾性研究：随访至少12个月并接受Xen或Trab术后丝裂霉素-C辅助治疗的受试者：主要结果测量：主要结果是 12 个月时的成功率，定义为眼压较基线降低≥ 20%，且眼压≤ 15mmHg、18mmHg 和 21mmHg 临界值，有（合格）或无（完全）药物治疗，且未进行二次青光眼手术。多变量混合效应考克斯回归模型用于确定每个队列中失败的风险因素：596名受试者中有701只眼睛（Xen组，308只；Trab组，393只）入选，Xen组与Trab组相比，基线眼压明显更高（22.4 mmHg vs 19.9 mmHg，p < 0.001），基线用药明显更少（2.9 mmHg vs 3.4 mmHg，p 结论：Xen组与Trab组相比，基线用药明显更少（2.9 mmHg vs 3.4 mmHg，p < 0.001）：在所有完全成功定义中，Trab组在12个月时的完全成功率明显高于Xen组，而Xen组的术后低张力率明显低于Trab组。亚裔和基线使用口服乙酰唑胺与 Xen 的更大失败率相关，而前列腺素类似物与 Trab 患者的更大失败率相关。这些成功和失败的基线预测因素有助于指导接受手术干预的患者选择结膜下微创青光眼手术。
{"title":"Outcomes and Baseline Predictors of Failure in Primary Standalone Xen45 Gel Stent versus Trabeculectomy for Glaucoma","authors":"Jeremy C.K. Tan MD, FRANZCO , Yohei Hashimoto MD, PhD , Pierre Henry Gabrielle PhD , Catherine Creuzot Garcher MD, PhD , Andrew White PhD, FRANZCO , Hamish Dunn MBBS, FRANZCO , Mark Walland FRANZCO, FRACS , David Wechsler MBBS, FRANZCO , Louis Arnould MD, PhD , Mitchell Lawlor PhD, FRANZCO","doi":"10.1016/j.ogla.2024.07.002","DOIUrl":"10.1016/j.ogla.2024.07.002","url":null,"abstract":"<div><h3>Purpose</h3><div>To compare safety, effectiveness, and baseline predictors of failure in standalone primary Xen45 gel stent (Xen) versus trabeculectomy (Trab) in glaucoma.</div></div><div><h3>Design</h3><div>Retrospective study.</div></div><div><h3>Subjects</h3><div>Subjects that underwent primary Xen or Trab augmented by mitomycin-C with at least 12 months follow-up.</div></div><div><h3>Methods</h3><div>Multinational observational study of eyes in the Fight Glaucoma Blindness international registry</div></div><div><h3>Main Outcome Measures</h3><div>The primary outcome was success at 12 months defined by intraocular pressure (IOP) reduction ≥ 20% from baseline and ≤ threshold IOPs of 15, 18, and 21 mmHg with (qualified) or without (complete) medications and without secondary glaucoma surgery. Multivariable mixed effects Cox regression models were used to identify risk factors for failure in each cohort.</div></div><div><h3>Results</h3><div>A total of 701 eyes (Xen, 308; Trab, 393) of 596 subjects were included with baseline IOP being significantly higher (22.4 vs. 19.9 mmHg, <em>P</em> < 0.001) and baseline medications significantly lower in the Xen versus the Trab group (2.9 vs. 3.4, <em>P</em> < 0.001). Baseline visual field mean deviation was less severe in the Xen group (–9.47 vs. –13.04 dB, <em>P</em> < 0.001). The proportion of complete surgical success was significantly lower in the Xen versus Trab group across the 3 upper IOP limits at 12 months; 32% versus 52% at 15 mmHg, 37% versus 54% at 18 mmHg, and 39% versus 55% at 21 mmHg (<em>P</em> < 0.001). The incidence of postoperative numerical and symptomatic hypotony was lower in the Xen versus Trab group. In the Xen cohort, a higher failure rate was associated with Asian ethnicity (hazard ratio [HR], 1.97; 95% confidence interval (CI), 1.03–3.79) and use of oral acetazolamide at baseline (HR, 1.74; 95% CI, 1.13–2.70), whereas a lower failure rate was associated with diagnosis of ocular hypertension/open-angle glaucoma suspect (HR, 0.40; 95% CI, 0.20–0.82) and secondary open-angle glaucoma (HR, 0.46; 95% CI, 0.26–0.82). Exposure to prostaglandin analog was associated with greater failure in the Trab group (HR, 2.66; 95% CI, 1.18–6.01).</div></div><div><h3>Conclusions</h3><div>There was significantly greater complete success at 12 months across all complete success definitions for Trab compared with Xen, whereas the rate of postoperative hypotony was significantly lower in the Xen group. Asian ethnicity and use of oral acetazolamide at baseline were associated with greater failure in Xen, whereas exposure to prostaglandin analog was associated with greater failure in Trab patients. Such baseline predictors of success and failure may help guide patient selection for subconjunctival minimally invasive glaucoma surgery in patients undergoing surgical intervention.</div></div><div><h3>Financial Disclosure(s)</h3><div>Proprietary or commercial disclosure may be found in the F","PeriodicalId":19519,"journal":{"name":"Ophthalmology. Glaucoma","volume":"7 6","pages":"Pages 539-550"},"PeriodicalIF":2.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141617695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.1016/j.ogla.2024.06.006
Irene Koc BS , Demetrios G. Vavvas MD, PhD , Teresa C. Chen MD
{"title":"Insight on the Optic Nerve and Ahmed Valve Tube through a Type II Keratoprosthesis","authors":"Irene Koc BS , Demetrios G. Vavvas MD, PhD , Teresa C. Chen MD","doi":"10.1016/j.ogla.2024.06.006","DOIUrl":"10.1016/j.ogla.2024.06.006","url":null,"abstract":"","PeriodicalId":19519,"journal":{"name":"Ophthalmology. Glaucoma","volume":"7 6","pages":"Page e13"},"PeriodicalIF":2.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141635974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.1016/j.ogla.2024.08.006
Vitor Porto de Souza MD , Fábio Nishimura Kanadani MD, PhD , Augusto Paranhos Jr. MD, PhD , Tiago Santos Prata MD, PhD
{"title":"Re: Chan et al.: Effect of preoperative trabecular meshwork pigmentation and other eye characteristics on outcomes of combined phacoemulsification/minimally invasive glaucoma surgery (Ophthalmol Glaucoma. 2024; 7:271-281)","authors":"Vitor Porto de Souza MD , Fábio Nishimura Kanadani MD, PhD , Augusto Paranhos Jr. MD, PhD , Tiago Santos Prata MD, PhD","doi":"10.1016/j.ogla.2024.08.006","DOIUrl":"10.1016/j.ogla.2024.08.006","url":null,"abstract":"","PeriodicalId":19519,"journal":{"name":"Ophthalmology. Glaucoma","volume":"7 6","pages":"Page e7"},"PeriodicalIF":2.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142382581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.1016/j.ogla.2024.06.002
Angela Liu BS , Lauren Dhar MD , Sarah Hung BS , Ronald Fellman MD , Davinder S. Grover MD, MPH
{"title":"Brief Report on 12-Month Outcomes of the ab Interno Gel Stent Using the Intraoperative Posterior Sweep of Tenons (PoST) Technique","authors":"Angela Liu BS , Lauren Dhar MD , Sarah Hung BS , Ronald Fellman MD , Davinder S. Grover MD, MPH","doi":"10.1016/j.ogla.2024.06.002","DOIUrl":"10.1016/j.ogla.2024.06.002","url":null,"abstract":"","PeriodicalId":19519,"journal":{"name":"Ophthalmology. Glaucoma","volume":"7 6","pages":"Pages 624-626"},"PeriodicalIF":2.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141332614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-01DOI: 10.1016/j.ogla.2024.07.008
Samuel Y. Lee BA , Megan E. Paul BA , Anne L. Coleman MD, PhD , Ken Kitayama MD, PhD , Fei Yu PhD , Deyu Pan MS , Victoria L. Tseng MD, PhD
Purpose
To investigate associations between statin use and glaucoma in the 2017 to 2022 All of Us (AoU) Research Program.
Design
Cross-sectional, population-based.
Participants
79 742 adult participants aged ≥40 years with hyperlipidemia and with electronic health record (EHR) data in the AoU database.
Methods
Hyperlipidemia, glaucoma status, and statin use were defined by diagnoses and medication information in EHR data collected by AoU. Logistic regression analysis was performed to evaluate the association between statin use and glaucoma likelihood. Logistic regression modeling was used to examine associations between glaucoma and all covariates included in adjusted analysis. Serum low-density lipoprotein cholesterol (LDL-C) was used to assess hyperlipidemia severity. Analyses stratified by LDL-C level and age were performed.
Main Outcome Measures
Any glaucoma as defined by International Classification of Diseases codes found in EHR data.
Results
Of 79 742 individuals with hyperlipidemia in AoU, there were 6365 (8.0%) statin users. Statin use was associated with increased glaucoma prevalence when compared with statin nonuse (adjusted odds ratio [aOR]: 1.13, 95% confidence interval [CI]: 1.01–1.26). Higher serum levels of LDL-C were associated with increased odds of glaucoma (aOR: 1.003, 95% CI: 1.003, 1.004). Statin users had significantly higher LDL-C levels compared to nonusers (144.9 mg/dL versus 136.3 mg/dL, P value < 0.001). Analysis stratified by LDL-C identified positive associations between statin use and prevalence of glaucoma among those with optimal (aOR = 1.39, 95% CI = 1.05–1.82) and high (aOR = 1.37, 95% CI = 1.09–1.70) LDL-C levels. Age-stratified analysis showed a positive association between statin use and prevalence of glaucoma in individuals aged 60 to 69 years (aOR = 1.28, 95% CI = 1.05–1.56).
Conclusions
Statin use was associated with increased glaucoma likelihood in the overall adult AoU population with hyperlipidemia, in individuals with optimal or high LDL-C levels, and in individuals 60 to 69 years old. Findings suggest that statin use may be an independent risk factor for glaucoma, which may furthermore be affected by one’s lipid profile and age.
Financial Disclosures
Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
{"title":"Associations between Statin Use and Glaucoma in the All of Us Research Program","authors":"Samuel Y. Lee BA , Megan E. Paul BA , Anne L. Coleman MD, PhD , Ken Kitayama MD, PhD , Fei Yu PhD , Deyu Pan MS , Victoria L. Tseng MD, PhD","doi":"10.1016/j.ogla.2024.07.008","DOIUrl":"10.1016/j.ogla.2024.07.008","url":null,"abstract":"<div><h3>Purpose</h3><div>To investigate associations between statin use and glaucoma in the 2017 to 2022 <em>All of Us</em> (<em>AoU</em>) Research Program.</div></div><div><h3>Design</h3><div>Cross-sectional, population-based.</div></div><div><h3>Participants</h3><div>79 742 adult participants aged ≥40 years with hyperlipidemia and with electronic health record (EHR) data in the <em>AoU</em> database.</div></div><div><h3>Methods</h3><div>Hyperlipidemia, glaucoma status, and statin use were defined by diagnoses and medication information in EHR data collected by <em>AoU</em>. Logistic regression analysis was performed to evaluate the association between statin use and glaucoma likelihood. Logistic regression modeling was used to examine associations between glaucoma and all covariates included in adjusted analysis. Serum low-density lipoprotein cholesterol (LDL-C) was used to assess hyperlipidemia severity. Analyses stratified by LDL-C level and age were performed.</div></div><div><h3>Main Outcome Measures</h3><div>Any glaucoma as defined by International Classification of Diseases codes found in EHR data.</div></div><div><h3>Results</h3><div>Of 79 742 individuals with hyperlipidemia in <em>AoU</em>, there were 6365 (8.0%) statin users. Statin use was associated with increased glaucoma prevalence when compared with statin nonuse (adjusted odds ratio [aOR]: 1.13, 95% confidence interval [CI]: 1.01–1.26). Higher serum levels of LDL-C were associated with increased odds of glaucoma (aOR: 1.003, 95% CI: 1.003, 1.004). Statin users had significantly higher LDL-C levels compared to nonusers (144.9 mg/dL versus 136.3 mg/dL, <em>P</em> value < 0.001). Analysis stratified by LDL-C identified positive associations between statin use and prevalence of glaucoma among those with optimal (aOR = 1.39, 95% CI = 1.05–1.82) and high (aOR = 1.37, 95% CI = 1.09–1.70) LDL-C levels. Age-stratified analysis showed a positive association between statin use and prevalence of glaucoma in individuals aged 60 to 69 years (aOR = 1.28, 95% CI = 1.05–1.56).</div></div><div><h3>Conclusions</h3><div>Statin use was associated with increased glaucoma likelihood in the overall adult <em>AoU</em> population with hyperlipidemia, in individuals with optimal or high LDL-C levels, and in individuals 60 to 69 years old. Findings suggest that statin use may be an independent risk factor for glaucoma, which may furthermore be affected by one’s lipid profile and age.</div></div><div><h3>Financial Disclosures</h3><div>Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.</div></div>","PeriodicalId":19519,"journal":{"name":"Ophthalmology. Glaucoma","volume":"7 6","pages":"Pages 563-571"},"PeriodicalIF":2.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141879932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号